![]() |
市場調查報告書
商品編碼
2085709
胃腸道支架市場:按產品類型、形式、應用、最終用戶和分銷管道分類的全球市場預測,2026-2032年Gastrointestinal Stents Market by Product Type, Form, Application, End User, Distribution Channel - Global Forecast 2026-2032 |
||||||
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計到 2032 年,胃腸道支架市場將成長至 7.4426 億美元,複合年成長率為 6.15%。
| 主要市場統計數據 | |
|---|---|
| 基準年 2025 | 4.899億美元 |
| 預計年份:2026年 | 5.2143億美元 |
| 預測年份 2032 | 7.4426億美元 |
| 複合年成長率 (%) | 6.15% |
胃腸道支架是現代介入內視鏡的核心,能夠以微創方式治療食道、胃、十二指腸、結腸、膽道和胰管的良性和惡性阻塞。自膨式金屬支架、塑膠支架、全覆膜支架、部分覆膜支架和管腔貼合式金屬支架均可用於恢復管腔通暢、促進引流、減輕吞嚥困難,並幫助患者避免高風險的外科手術。
胃腸道支架領域正從傳統的減壓療法轉向精準的、針對特定適應症的器械設計。醫院和門診內視鏡中心擴大根據支架的徑向支撐力、軸向柔軟性、覆蓋材料、防移位性能、可取出性以及與先進內超音波超音波的兼容性來選擇支架。
人工智慧 (AI) 正透過早期病變檢測、治療方案製定、器械選擇和術後監測等方式,開始對胃腸道支架領域產生影響。人工智慧輔助內視鏡已在檢測胃腸道異常方面展現出臨床效用,美國食品藥物管理局(FDA) 已批准到 2024 年將有超過 950 種搭載人工智慧/機器學習 (ML) 技術的醫療設備上市。這反映出醫療保健產業對檢驗的臨床演算法的監管認可度正在不斷提高。
在亞太地區,隨著中國、印度、日本、韓國和澳洲等國加大對內視鏡基礎設施和癌症治療系統的投資,市場正在不斷擴張。世界衛生組織/國際癌症研究機構的數據顯示,東亞地區胃癌和食道癌的發生率尤其高,凸顯了三級醫療機構和癌症轉診中心對膽道、食道、十二指腸和結直腸支架置入術的持續臨床需求。
在東南亞國協,治療性內視鏡的普及程度正在提高,尤其是在新加坡、泰國、馬來西亞、印尼、越南和菲律賓,這得益於對公立醫院、私立專科醫療中心和醫療旅遊中心的投資。在海灣合作理事會國家,支架植入術的應用正在加速,這得益於先進的急診醫院、癌症中心以及政府主導的醫療改革項目,這些項目強調先進的微創手術和專業的胃腸道護理。
美國在先進治療性內視鏡、人工智慧成像技術以及新型胃腸支架設計的早期臨床應用方面處於主導。而加拿大則強調實證採購和各省醫療保健系統內的公平取得。在墨西哥和巴西,隨著腫瘤科和胃腸病科服務的擴展,需求不斷成長,但成本敏感性和地區差異正在影響高價醫療設備的供應。
產業領導者應優先考慮具有臨床差異化的胃腸道支架產品組合,以應對支架移位、組織侵入、取出便利性、部署產品系列、徑向力平衡以及與超音波超音波引導引流的兼容性等挑戰。投資於醫生培訓、指導教師指導、模擬教學以及針對特定手術的臨床支持,可以加速產品推廣應用,並降低與併發症相關的差異性。
本執行摘要基於法律規範,包括世界衛生組織/國際癌症研究機構全球癌症監測網路(WHO/IARC GLOBOCAN)的癌症統計數據、美國食品藥品監督管理局(FDA)的醫療設備和人工智慧/機器學習賦能器械註冊清單、胃腸病學會指南、同行檢驗的臨床文獻、監管框架以及醫療基礎設施資訊來源。研究透過橫斷面匹配臨床、監管、技術和區域需求訊號得出相關見解。
由於全球癌症、良性胃腸道狹窄、膽道阻塞等疾病負擔日益加重,以及對微創介入治療需求不斷成長,胃腸道支架市場預計將繼續佔據重要地位。器械創新正朝著更佳的貼合度、可控的展開、防移位技術、改進的覆膜以及在先進內視鏡手術中更廣泛的應用方向發展。
The Gastrointestinal Stents Market is projected to grow by USD 744.26 million at a CAGR of 6.15% by 2032.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2025] | USD 489.90 million |
| Estimated Year [2026] | USD 521.43 million |
| Forecast Year [2032] | USD 744.26 million |
| CAGR (%) | 6.15% |
Gastrointestinal stents are central to modern interventional endoscopy, enabling minimally invasive treatment of malignant and benign obstructions across the esophagus, stomach, duodenum, colon, biliary tract, and pancreatic duct. Self-expanding metal stents, plastic stents, fully covered devices, partially covered devices, and lumen-apposing metal stents are used to restore luminal patency, support drainage, reduce dysphagia, and help patients avoid higher-risk surgical interventions.
Demand is supported by measurable disease burden. WHO/IARC GLOBOCAN 2022 data show colorectal cancer exceeded 1.9 million new cases globally, while stomach cancer accounted for more than 960,000 new cases and esophageal cancer for more than 510,000 new cases. These conditions frequently require palliative or bridge-to-surgery stenting, making gastrointestinal stents a high-value segment within endoscopy devices, gastroenterology care, and minimally invasive cancer management.
The gastrointestinal stents landscape is shifting from conventional decompression toward precision, indication-specific device design. Hospitals and ambulatory endoscopy centers are increasingly selecting stents based on radial force, axial flexibility, covering material, anti-migration performance, removability, and compatibility with advanced endoscopic ultrasound procedures.
Adoption is also being shaped by value-based care and clinical guideline alignment. Endoscopic stenting can shorten time to oral intake, reduce repeat interventions when appropriately selected, and support palliation in patients who are not surgical candidates. The field is moving toward safer deployment systems, better imaging guidance, improved biocompatible coverings, and evidence-based protocols aligned with gastroenterology society recommendations for biliary, esophageal, gastroduodenal, and colorectal obstruction management.
Artificial intelligence is beginning to influence gastrointestinal stents through earlier lesion detection, procedure planning, device selection, and post-procedure monitoring. AI-assisted endoscopy has demonstrated clinical utility in detecting gastrointestinal abnormalities, and the U.S. FDA listed more than 950 AI/ML-enabled medical devices by 2024, reflecting broader regulatory acceptance of validated clinical algorithms across healthcare.
For stent manufacturers and providers, cumulative AI impact is expected in predictive sizing, migration-risk assessment, fluoroscopy workflow optimization, inventory planning, complication surveillance, and real-world evidence generation. However, AI must remain clinically validated, transparent, and supervised by trained specialists because stent placement requires anatomical judgment, complication management, and patient-specific decision-making.
Asia-Pacific is expanding as China, India, Japan, South Korea, and Australia invest in endoscopy infrastructure and cancer care capacity. WHO/IARC data indicate a high concentration of gastric and esophageal cancer burden in East Asia, supporting sustained clinical need for biliary, esophageal, duodenal, and colorectal stenting across tertiary hospitals and oncology referral centers.
North America benefits from advanced endoscopy adoption, established reimbursement pathways, and strong use of self-expanding metal stents in tertiary cancer centers and high-volume therapeutic endoscopy units. Latin America shows growing demand in Brazil and Mexico as oncology and gastroenterology services expand, although uneven access and device affordability continue to influence uptake. Europe is shaped by standardized clinical guidance, specialist endoscopy networks, and the EU Medical Device Regulation, which increases emphasis on clinical evidence, post-market surveillance, and device traceability. The Middle East is supported by hospital modernization in GCC countries and rising investment in oncology care, while Africa remains opportunity-rich but constrained by specialist availability, affordability, procurement limitations, and limited therapeutic endoscopy coverage in many health systems.
ASEAN countries are improving access to therapeutic endoscopy through public hospital investment, private specialty centers, and medical tourism hubs, particularly in Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines. The GCC is accelerating adoption through high-acuity hospitals, oncology centers, and government-backed health transformation programs that favor advanced minimally invasive procedures and specialist gastrointestinal care.
The European Union emphasizes clinical evidence, post-market surveillance, and regulatory conformity under the Medical Device Regulation, creating a quality-driven environment for gastrointestinal stent approvals and procurement. BRICS economies represent volume-led opportunity because of large patient populations, expanding cancer services, and increasing hospital capacity in China, India, Brazil, Russia, and South Africa. G7 markets lead in innovation, clinical trials, endoscopic ultrasound adoption, and reimbursement sophistication, while NATO countries benefit from mature hospital procurement systems, interoperability expectations, and cross-border standardization in medical technology quality and safety requirements.
The United States leads in advanced therapeutic endoscopy, AI-enabled imaging adoption, and early clinical use of novel gastrointestinal stent designs, while Canada emphasizes evidence-based procurement and equitable access across provincial health systems. Mexico and Brazil show rising demand as oncology and gastroenterology services expand, although cost sensitivity and regional disparities affect premium device uptake.
In Europe, the United Kingdom, Germany, France, Italy, and Spain maintain strong demand through cancer networks, specialist endoscopy centers, and guideline-based management of malignant obstruction and biliary disease, while Russia's environment is influenced by localization priorities, procurement constraints, and access variation. China and India offer substantial clinical need from large patient pools, high gastrointestinal cancer burden, and expanding hospital capacity; Japan and South Korea remain innovation-intensive markets with high endoscopy utilization and strong specialist expertise. Australia benefits from organized cancer care pathways, specialist access, quality standards, and adoption of minimally invasive gastrointestinal interventions in major public and private hospitals.
Industry leaders should prioritize clinically differentiated gastrointestinal stent portfolios that address migration, tissue ingrowth, ease of removal, deployment accuracy, radial force balance, and compatibility with EUS-guided drainage. Investments in physician training, proctoring, simulation-based education, and procedure-specific clinical support can strengthen adoption and reduce complication-related variability.
Manufacturers should build evidence through registries, real-world outcomes, and comparative studies across malignant obstruction, benign strictures, biliary drainage, pancreatic duct management, and colorectal decompression. Commercial strategy should combine premium innovation in mature markets with cost-optimized products for emerging economies, supported by resilient supply chains, local regulatory expertise, post-market surveillance readiness, and region-specific access strategies.
This executive summary is based on secondary research from publicly available and verifiable sources, including WHO/IARC GLOBOCAN cancer statistics, U.S. FDA medical device and AI/ML-enabled device listings, gastroenterology society guidance, peer-reviewed clinical literature, regulatory frameworks, and healthcare infrastructure indicators. Insights were triangulated across clinical, regulatory, technological, and regional demand signals.
The methodology emphasizes data reliability, source consistency, and market relevance while avoiding unsupported estimates. Findings were evaluated through disease burden, procedure adoption, reimbursement environment, device innovation, hospital capacity, regulatory requirements, and competitive positioning to identify durable opportunities in the gastrointestinal stents market.
The gastrointestinal stents market is positioned for continued relevance as cancer burden, benign gastrointestinal strictures, biliary obstruction, and demand for minimally invasive interventions increase worldwide. Device innovation is moving toward better conformability, controlled deployment, anti-migration engineering, improved coverings, and expanded use in advanced endoscopic procedures.
Future progress will depend on evidence-backed differentiation, regulatory compliance, clinical training, and affordability across diverse healthcare systems. Organizations that integrate AI-supported workflows, real-world evidence, and region-specific access strategies will be best positioned to compete in this essential endoscopy device segment.